Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1B
pubmed:dateCreated
2003-4-8
pubmed:abstractText
The interaction between paclitaxel and its target, beta tubulin, is essential for effective cytotoxicity. Alterations or mutation of beta tubulin have the potential to alter paclitaxel binding and confer a drug resistant phenotype.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0250-7005
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
681-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12680167-Adult, pubmed-meshheading:12680167-Aged, pubmed-meshheading:12680167-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12680167-Carboplatin, pubmed-meshheading:12680167-Cisplatin, pubmed-meshheading:12680167-Combined Modality Therapy, pubmed-meshheading:12680167-DNA, Neoplasm, pubmed-meshheading:12680167-Exons, pubmed-meshheading:12680167-Female, pubmed-meshheading:12680167-Humans, pubmed-meshheading:12680167-Middle Aged, pubmed-meshheading:12680167-Ovarian Neoplasms, pubmed-meshheading:12680167-Paclitaxel, pubmed-meshheading:12680167-Point Mutation, pubmed-meshheading:12680167-Polymerase Chain Reaction, pubmed-meshheading:12680167-Polymorphism, Single-Stranded Conformational, pubmed-meshheading:12680167-Retrospective Studies, pubmed-meshheading:12680167-Tubulin
pubmed:articleTitle
beta tubulin mutations are rare in human ovarian carcinoma.
pubmed:affiliation
Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't